Mineralys Therapeutics
$25.59
21
+$1.60+6.67% Today
Statistics
Day High
25.67
Day Low
24.26
52W High
47.65
52W Low
12.59
Volume
107,217,964
Avg. Volume
-
Mkt Cap
2.03B
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Earnings
18AugExpected
Expected EPS
-0.548571
Actual EPS
N/A
Financials
-Profit Margin
Unprofitable0Revenue
-355.62MNet Income
Analyst Ratings
51.00Average Price Target
The highest estimate is 51.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy 100%
Hold 0%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow MLYS. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Ardelyx
ARDX
Mkt Cap1.41B
Aurinia Pharmaceuticals
AUPH
Mkt Cap2.03B
Trevena
TRVN
Mkt Cap9,501
Akebia Therapeutics
AKBA
Mkt Cap248M
Amarin
AMRN
Mkt Cap319.57M
Galmed Pharmaceuticals
GLMD
Mkt Cap4.04M
About
Mineralys Therapeutics, Inc. (MLYS) is a pioneering biopharmaceutical company currently advancing through clinical trials. Its primary focus lies in creating innovative treatments for high blood pressure and its related cardiovascular complications. The company's leading investigational drug is lorundrostat. This exclusive, orally administered compound functions as a highly targeted aldosterone synthase inhibitor, specifically being developed to address difficult-to-treat cases of uncontrolled or resistant hypertension. Established in 2019, Mineralys Therapeutics operates from its headquarters in Radnor, Pennsylvania.
Show more...
CEO
Dr. Jon Congleton
Employees
51
Country
United States
ISIN
US6031701013
Listings
0 Comments
Share your thoughts
FAQ
What is Mineralys Therapeutics stock price today?▼
The current price of MLYS is $25.59 USD — it has increased by +6.67% in the past 24 hours. Watch Mineralys Therapeutics stock price performance more closely on the chart.
What is Mineralys Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Mineralys Therapeutics stocks are traded under the ticker MLYS.
Is Mineralys Therapeutics stock price growing?▼
MLYS stock has risen by +6.94% compared to the previous week, the month change is a -7.2% fall, over the last year Mineralys Therapeutics has showed a +84.4% increase.
What is Mineralys Therapeutics market cap?▼
Today Mineralys Therapeutics has the market capitalization of 2.03B
When is the next Mineralys Therapeutics earnings date?▼
Mineralys Therapeutics is going to release the next earnings report on August 18, 2026.
What were Mineralys Therapeutics earnings last quarter?▼
MLYS earnings for the last quarter are -0.47 USD per share, whereas the estimation was -0.47 USD resulting in a +0.46% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Mineralys Therapeutics revenue for the last year?▼
Mineralys Therapeutics revenue for the last year amounts to 0 USD.
What is Mineralys Therapeutics net income for the last year?▼
MLYS net income for the last year is -355.62M USD.
How many employees does Mineralys Therapeutics have?▼
As of June 17, 2026, the company has 51 employees.
In which sector is Mineralys Therapeutics located?▼
Mineralys Therapeutics operates in the Health & Wellness sector.
When did Mineralys Therapeutics complete a stock split?▼
Mineralys Therapeutics has not had any recent stock splits.
Where is Mineralys Therapeutics headquartered?▼
Mineralys Therapeutics is headquartered in Radnor, United States.